We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Device May Provide Rapid POC Assessment of Clot Ability

By Michal Siman-Tov
Posted on 13 Dec 2016
Researchers have developed a sensor that, on initial testing, accurately assessed blood-clotting ability 95 times faster than current methods, which uses only a single drop of blood. More...
The device also provided more information than existing approaches.

The new device, “ClotChip,” was developed by researchers at Case Western Reserve University (CWRU; Cleveland, OH, USA) to provide rapid and accurate assessments essential for providing appropriate care for patients with blood clotting problems. XaTek, a new Cleveland-based company, has licensed the technology for ClotChip with a goal of bringing it to market within three years.

“ClotChip is designed to minimize the time and effort for blood-sample preparation. [It can] be used at the doctor’s office or other points-of-care for patients on anticoagulation therapy, antiplatelet therapy, or who have suffered a traumatic injury causing bleeding,” said Pedram Mohseni, professor of electrical engineering and computer science (EECS) at CWRU, who led the development of ClotChip with Michael Suster, an EECS senior research associate.

Existing measures typically require patients to visit laboratories where expert technicians administer tests, an approach that typically is time-consuming and expensive. While a few methods exist to allow on-site testing, to date they have not been nearly as precise as laboratory-based methods.

In preliminary tests ClotChip provided results in 15 minutes, as compared to current measures that can take a day or even longer. It also provided more information about the coagulation process, including effects of a relatively new class of drugs – target-specific oral anticoagulants (TSOACs).

TSOACs block clots from forming in a different way than warfarin (e.g. brand name Coumadin). Warfarin can interact negatively with several medications and foods and also requires frequent blood tests to monitor the drug’s effects. The new medications, including rivaroxaban (Xarelto) and apixaban (Eliquis), have been marketed as a far more convenient alternative. To date, however, the US Food and Drug Administration (FDA) has not approved a device to determine the impact of the new drugs.

With use of TSOACs growing rapidly, “there’s a huge opportunity and need,” said John Zak, president and CEO of XaTek, “There’s no readily available point-of-care, cost-effective, and accurate way to monitor these drugs.” He said the company hopes to complete a pilot clinical study and data analysis of ClotChip use on 200 patients at the Louis Stokes Cleveland VA Medical Center by the end of 2017. If the device proves effective in that initial evaluation, XaTek would seek to launch a full clinical trial within the following two years; and from there would seek FDA approval.

To monitor clotting, ClotChip uses an electrical technique called miniaturized dielectric spectroscopy, an approach that Prof. Mohseni, Dr. Suster, and team began developing six years ago. In essence, the technique applies an external electric field to the drop of blood, then quantitatively measures how the blood affects that field. The measurements reflect ability of the blood to clot. They then began collaborating with Evi Stavrou, assistant professor of hematology and oncology, Case Western Reserve School of Medicine. The three researchers are also investigators at Advanced Platform Technology (APT) Research Center.

The team found that ClotChip's sensitivity to the blood coagulation process made it an appealing option for point-of-care testing. “Our device gives you different information—and more information—than other devices out there,” said Prof. Stavrou, “The sensitivity and discriminatory ability of the device, when compared to standard coagulation tests, is what excites me very much.” And the device works so quickly that emergency responders could use it on site to determine whether a patient in trauma is on one of the blood-thinner medications. Such critical information also could be invaluable to medics in wartime.

Related Links:
Case Western Reserve University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.